| abstract |
The invention describes recombinant adenoviral vectors in which the E1 and/or E3 reading frames have been removed and which contain a therapeutic gene that is selected, inter alia, from amongst the human urokinase plasminogen activator gene (huPA), the truncated type II TGF-beta receptor gene and the human hepatocyte growth factor gene (HGF). The invention also describes methods for the preparation of vectors, compositions prepared with said vectors and their use in genic therapy of cirrhosis and other types of fibrosis. |